First regional consensus on the management of Helicobacter pylori infection in the Middle East

World J Gastroenterol. 2025 Jul 21;31(27):107138. doi: 10.3748/wjg.v31.i27.107138.

Abstract

Helicobacter pylori (H. pylori), a widespread gram-negative bacterium that colonizes the stomach, causes chronic gastritis, which may progress to peptic ulcer, mucosa-associated lymphoid tissue lymphoma, and gastric cancer. H. pylori infection affects over 50% of people in developing countries and 10%-20% in developed countries. The Kyoto consensus classifies H. pylori gastritis as an infectious disease in the International Classification of Disease 11th Revision. The Maastricht/Florence consensus recommends treatment for all infected individuals, introducing a shift in the management strategies. The prevalence of H. pylori infection is high in the Middle East, with infection rates of 40%-70% and 85%-90% being reported among children and adults, respectively. The increasing resistance to antibiotics, including macrolides and fluoroquinolones, is a major challenge in the management of H. pylori. Clarithromycin resistance, which is associated with reduced effectiveness of standard triple therapy regimens, leading to higher rates of treatment failure, impacts the eradication rates. This emphasizes the need for routine antibiotic susceptibility testing at the national level, the use of alternative therapies, including new molecular methods, and antibiotic stewardship. An online panel of experts from the Middle East, along with an international expert, developed this consensus to provide comprehensive guidelines on the diagnosis, treatment, prevention, and role of gut microbiota in H. pylori infection, with the goal of improving clinical decision-making and reducing the impact of antibiotic resistance in the region. These guidelines are intended to support healthcare professionals involved in the diagnosis and management of H. pylori, including primary care physicians, gastroenterologists, and other specialists. They may also inform future clinical research aimed at optimizing treatment strategies and addressing regional challenges.

Keywords: Antibiotic resistance; Consensus guidelines; Gastric cancer; Gut microbiota; Helicobacter pylori.

Publication types

  • Consensus Statement
  • Practice Guideline

MeSH terms

  • Anti-Bacterial Agents* / pharmacology
  • Anti-Bacterial Agents* / therapeutic use
  • Antimicrobial Stewardship / standards
  • Drug Resistance, Bacterial
  • Drug Therapy, Combination / standards
  • Gastritis* / diagnosis
  • Gastritis* / drug therapy
  • Gastritis* / epidemiology
  • Gastritis* / microbiology
  • Helicobacter Infections* / diagnosis
  • Helicobacter Infections* / drug therapy
  • Helicobacter Infections* / epidemiology
  • Helicobacter Infections* / microbiology
  • Helicobacter Infections* / therapy
  • Helicobacter pylori* / drug effects
  • Helicobacter pylori* / isolation & purification
  • Humans
  • Microbial Sensitivity Tests
  • Middle East / epidemiology
  • Prevalence
  • Proton Pump Inhibitors / therapeutic use

Substances

  • Anti-Bacterial Agents
  • Proton Pump Inhibitors